Lumigan and/or Equivalent Bimatoprost Ophthalmic Prescription Information
Lumigan is a Prostaglandin Analog which is used for the treatment of Ocular Hypertension. It contains Bimatoprost as an active ingredient. It manages intraocular pressure by enhancing outflow rate of the fluids which are secreted in the eyes.
Lumigan is approved for the treatment of Ocular Hypertension in patients with open angle glaucoma. It is also used in the treatment of the progression of Glaucoma. Bimatoprost is also approved by US FDA in December 2008 for its cosmetic use as lengthening of eyelashes. It is also reported in recent studies that bimatoprost also has ability to reduce Adipose (fat) tissues. It should be used only in patients above 16 years as it is studied only in such population.
Lumigan is manufactured in topically administered solution formulation. This solution is available in two strengths as bimatoprost 0.1 mg/mL and 0.3 mg/mL. This solution contains benzalkonium chloride as a preservative. Lumigan should be administered as prescribed by ophthalmologist or one drop in the affected eye(s) 1x/day in the evening as more than 1x/day may decrease its potency of lowering intraocular pressure. It shows its action after around 4 hours of administration and reaches to maximum effect in about 8 to 12 hours. It should be stored at 2C to 25C (36F to 77F).
If any patient is contact lenses user then these lenses must be removed before administration of the Lumigan and should be replaced after 15 minutes of its administration.
Mechanism of action:
Lumigan contains bimatoprost an active ingredient which is a new synthetic structural prostaglandin analog. Bimatoprost shows ocular hypotensive effects primarily by 26% reduction in the tonographic resistance to outflow. It also helps in stimulation of the aqueous humor flow rate by enhancing the pressure-sensitive outflow pathway. It lowers intraocular pressure (IOP) via both the trabecular meshwork and uveoscleral routes. Reduced tonographic resistance to aqueous humor outflow results in reducing the steady state IOP which is actually required for the treatment of glaucoma. Its reduction in outflow resistance property is an exclusive to bimatoprost.
Its use in patients below the age of 16 years is not recommended because of potential safety issue related to increased pigmentation.
After stopping Lumigan therapy, the pigmentation and darkening of eye color likely to be permanent.
Don't touch the tip of dispensing bottle as this may lead to contamination of solution, which may seriously damage to eyes. Bacterial keratitis has been reported with the use of multiple-dose containers.
Iris color may change to brown and may remain unnoticed for several months to years.
Macular edema has been reported during bimatoprost therapy, so it should be used with caution in aphakic patients, or in patients with macular edema.
Bimatoprost is categorized as pregnancy category C drug. Abortion has been reported in preclinical studies with 33 to 97 doses, so, it must not be used in pregnant women.
It has been reported in preclinical studies that bimatoprost excretes via breast milk, so it must not be prescribed to nursing women.
Want Help Ordering Lumigan Online?
Do you want to buy Lumigan online but have questions? Call 1-877-275-1525 or contact us through another method. We are here to help. Once you have placed your order for Lumigan, you will be provided with instruction on how to submit your doctors prescription.
Lumigan Lowest Price Guarantee
Our mission at CanadaDrugPharmacy.com is to offer Lumigan at the most affordable price along with exceptional customer service. We are so confident we have the cheapest price for Lumigan, if you find a cheaper price online, use the price beat feature next to the medication and we will beat it.
The products listed below either match, relate to, or are possibly therapeutically equivalent to "Lumigan". Please note that all prescription products require a VALID PRESCRIPTION written by your doctor to be sent to us to complete your order.
All generic products listed above are NOT manufactured or authorized by the maker of the brand name product. They are manufactured by licensed generic manufacturers.
IMPORTANT DISCLOSURE: All medical content and news articles on this website is supplied by an independent third party company. While the information can be useful, this website relies on others for its creation and cannot guarantee the accuracy, medical efficacy, or reliability of the information provided. In all circumstances, you should always seek the advice of your physician and/or other qualified health professional(s) for drug, medical condition, or treatment advice. This website does not provide any medical advice. The content provided on this website is not a substitute for professional medical advice, diagnosis or treatment.